Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Spruce Biosciences (SPRB) Debt to Equity (2021 - 2025)

Spruce Biosciences has reported Debt to Equity over the past 5 years, most recently at $0.1 for Q3 2025.

  • Quarterly Debt to Equity rose 140.8% to $0.1 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $0.1 through Sep 2025, up 140.8% year-over-year, with the annual reading at $0.06 for FY2024, 38.81% up from the prior year.
  • Debt to Equity was $0.1 for Q3 2025 at Spruce Biosciences, up from $0.07 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.1 in Q3 2025 and troughed at $0.04 in Q3 2024.
  • The 5-year median for Debt to Equity is $0.05 (2022), against an average of $0.06.
  • Year-over-year, Debt to Equity tumbled 39.19% in 2023 and then surged 140.8% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.04 in 2021, then surged by 63.85% to $0.07 in 2022, then tumbled by 39.19% to $0.04 in 2023, then surged by 38.81% to $0.06 in 2024, then skyrocketed by 65.19% to $0.1 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Debt to Equity are $0.1 (Q3 2025), $0.07 (Q2 2025), and $0.09 (Q1 2025).